The scrutiny follows allegations of data manipulation and misleading claims about the drug's effectiveness, leading the Securities and Exchange Commission to charge the company, which resulted in a ...

In terms of valuation, Cassava Sciences Inc’s market capitalization stands at $1.29 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

The SEC has fined Cassava Sciences $40 million for misleading investors on the company's Alzheimer's drug candidate simufilam ...

The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

The SEC announced last week that it had filed a complaint against Cassava Sciences, Inc., a “pharmaceutical company with one primary drug ...

Try this creamy scalloped cassava casserole, a flavorful and comforting side dish. Made with tender cassava and a rich, ...

Enston specifically references eleven ingredients — beans, cassava, coconut and rice among them — which make up the backbone ...

Sep. 18, 2024 — A team of scientists alarmed by the loss of biodiversity across the world due to climate change has proposed a new approach to managing vulnerable ... Rugged Falklands Landscape ...

Before market open, Cassava announced that it has reached agreement with the U.S. Securities and Exchange Commission (SEC) to ...

Biopharmaceutical company Cassava Sciences, along with founder Remi Barbier and former Senior Vice President of Neuroscience Lindsay Burns, PhD, will pay more than $40 million to settle allegations ...

Neuroscience-focused biopharmaceutical company Cassava Sciences Inc. and two former executives have agreed to pay over $40 ...